KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Debt to Equity (2016 - 2026)

Bristol Myers Squibb has reported Debt to Equity over the past 18 years, most recently at $2.22 for Q1 2026.

  • Quarterly Debt to Equity fell 98.7% to $2.22 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.22 through Mar 2026, down 98.7% year-over-year, with the annual reading at $2.44 for FY2025, 26.66% down from the prior year.
  • Debt to Equity was $2.22 for Q1 2026 at Bristol Myers Squibb, down from $2.44 in the prior quarter.
  • Over five years, Debt to Equity peaked at $910.83 in Q2 2025 and troughed at -$46.49 in Q3 2022.
  • The 5-year median for Debt to Equity is $2.44 (2025), against an average of $126.94.
  • The largest YoY upside for Debt to Equity was 65455.05% in 2022 against a maximum downside of 4702.23% in 2022.
  • A 5-year view of Debt to Equity shows it stood at -$30.69 in 2022, then grew by 16.19% to -$25.73 in 2023, then surged by 112.94% to $3.33 in 2024, then fell by 26.66% to $2.44 in 2025, then dropped by 9.28% to $2.22 in 2026.
  • Per Business Quant, the three most recent readings for BMY's Debt to Equity are $2.22 (Q1 2026), $2.44 (Q4 2025), and $2.63 (Q3 2025).